Öz
Aim: To investigate the efficacy of
progesterone vaginal gel on endometrial
hyperplasias.
Material and Methods: Twelve patients
who admitted our gynecology clinic with
irregular menstrual bleeding and were
diagnosed as endometrial hyperplasia with
endometrial sampling were included. Group 1
(n=6) received progesterone vaginal gel
(Crinone 8% vaginal gel, Serono
Pharmaceuticals, Turkey) daily, between 15-
25th cycle days, whereas Group 2 (n=6)
received Dydrogesterone (Duphaston 10 mg.tb,
Solvay, Turkey) per os twice daily, between
15-25th cycle days for three months.
Endometrial pathological findings, endometrial
thickness before and after treatment, blood
lipid profile were compared between groups.
Statistical analysis were performed in SPSS for
windows version 10.0 using Wilcoxon Signed
ranks test and Mann-Whitney U test. P<0,05
was considered statisticaly significant.
Results: Endometrial hyperplasia was
treated in 4 patient ( 66,6%) in Group 1 and 5
patients (%83,3) in Group 2. Lipid profile was not statistically significantly different between
groups. Endometrial thickness decreased
significantly after treatment when compared to
pre-treatment (p<0,05). Uterine artery rezistans
index increased significantly in Group 1
(p<0,05), wheras no changes was observed in
Group 2 (p>0,05).
Conclusion: Crinone 8% vaginal gel was
found effective in the treatment of endometrial
hyperplasia. Decreased uterine blood flow may
play a role in this effect. It has not any adverse
effect on blood lipid profile
Anahtar Kelimeler
Crinone gel, dydrogesterone, endometrial hyperplasia, blood lipid profile, uterine artery Dopler
Kaynakça
- Lacey CG. Premalignant & malignant disorders of the uterine corpus. In : Pernoll ML. Current. Obstetrics&Gynecologic Diagnosis&Treatment. Seventh edd. Lebanon: Appleton&Lange,1991:955- 973.
- Kurman RJ, Kaminski PF, Norris JH ve ark. The behavior of endometrial hyperplasia: A long term study of untreated hyperplasia in 170 patients. Cancer 1985; 56: 403-407.
- Gal D, Edman CD, Vellios F ve ark. Long-term effect of megestrol acetate in the treatment of endometrial hyperplasia. Am J Obstet Gynecol;1983: 146(3): 316-22.
- Gal D. Hormonal therapy for lesions of the endometrium. Semin Oncol 1986; 13 (4Supp4):33-6.
- Faludi AA, Aldrighi JM, Bertolami MC ve ark. Progesterone abolishes estrogen and/or atorvastatin endothelium dependent vasodilatory effects. Atherosclerosis 2004; 177(1): 89-96.
- Chantilis SJ, Zeitoun KM, Patel SI ve ark. Use of Crinone vaginal progesterone gel for luteal support in in vitro fertilization cycles. Fertil Steril 1999; 72(5):823-9.
- Levine H. Luteal support in IVF using the novel vaginal progesterone gel Crinone 8%: results of an open-label trial in 1184 women from 16 US centers. Fertil Steril 2000;74(4):836-7.
- Banz C, Katalinic A, Al-Hasani S ve ark. Preparation of cycles for cryopreservation transfers using estradiol patches and Crinone 8% vaginal gel is effective and does not need any monitoring. Eur J Obstet Gynecol Reprod Biol 2002;103(1):43-7.
- Casanas-Roux F, Nisolle M, Marbaix E ve ark. Morphometric, immunohistological and three- dimensional evaluation of the endometrium of menopausal women treated by oestrogen and Crinone, a new slow-release vaginal progesterone. Hum Reprod 1996; 11(2): 357-63.
- Warren MP, Biller BM, Shangold MM. A new clinical option for hormone replacement therapy in women with secondary amenorrhea: effects of cyclic administration of progesterone from the sustained-release vaginal gel Crinone (4% and 8%) on endometrial morphologic features and withdrawal bleeding. Am J Obstet Gynecol1999;180(1Pt1):42-8.